.png)
Eyes on AstraZeneca
- Jana Chisholm
- 4 hours ago
- 2 min read
AstraZeneca doubles down on $80B target amid catalyst-rich 2026 pipeline. With more than 100 phase 3 trials underway with 20+ readouts expected this year, the company faces both blockbuster opportunity and Farxiga's patent cliff risk.
A Catalyst-Dense Year Ahead
AstraZeneca ended 2025 with fourth-quarter revenue of $15.5 billion, slightly exceeding expectations, driven primarily by oncology.
But analysts are focused less on commercial performance and more on the company’s extraordinary clinical calendar.
Management reported:
100+ ongoing phase 3 trials
20+ major late-stage readouts expected in 2026
The breadth is designed to diversify risk and support AstraZeneca’s ambition to exceed $80 billion in annual revenue by 2030.
Key AstraZeneca Programs to Watch
Among the most closely watched readouts:
Serena-4: Oral SERD camizestrant in first-line HR-positive breast cancer
Cambria-1 and Cambria-2: Adjuvant breast cancer settings
Avanzar: Datroway in first-line NSCLC, supported by AI-derived TROP2 biomarker
Efzimfotase alpha: Three phase 3 trials in hypophosphatasia
CardioTTRansform: Wainua in ATTR-CM
Tozorakimab: Three phase 3 trials in COPD
The Datroway program reflects AstraZeneca’s growing use of AI in trial design. Through collaborations with Tempus AI and Pathos AI, the company developed a multimodal oncology model to optimize patient selection.
Beyond Oncology: Rare Disease and Cardiometabolic Expansion
Efzimfotase alpha is positioned as a potential $3–$5 billion peak sales opportunity outside oncology. The therapy’s biweekly dosing improves upon Strensiq’s frequent administration schedule.
In cardiology, AstraZeneca aims to penetrate the competitive ATTR-CM market. CardioTTRansform includes subgroup analyses among patients on Vyndamax, potentially informing combination strategies.
The Farxiga Question
A major headwind looms:
Farxiga generated $8.4 billion in 2025.
The drug faces patent expiration pressure.
It is among the first medications subject to IRA Medicare price negotiation.
Management acknowledges a “bump” in the biopharma division but argues sufficient growth drivers exist.
Potential offsets include:
2026 launch of baxdrostat (resistant hypertension)
Continued double-digit growth from Breztri and Tezspire
Outlook: Execution Will Define the Decade
AstraZeneca’s scale provides diversification. However, sustaining the pace of phase 3 success will be critical. With concentration risk relatively low but execution complexity high, 2026 may represent the most important validation year in the company’s push toward its 2030 ambition.
